Methadone can be detected in urine drug screening tests even when a patient is concurrently taking trimipramine, a tricyclic antidepressant. However, there is evidence that tricyclic antidepressants, such as trimipramine, can sometimes cause false positive results for methadone in enzyme immunoassay-based urine drug screens. This occurs because these immunoassays may cross-react with the tricyclic compounds, potentially leading to a false positive methadone result.
Because of this, UK guidelines recommend that any questionable enzyme immunoassay screening results, especially when involving tricyclic antidepressants, should be confirmed by an appropriate chromatographic technique, which is more specific and can differentiate methadone from tricyclic antidepressants and their metabolites.
Therefore, while methadone itself would normally be detected in urine tests during treatment and has an estimated detectability window of 3–4 days, the concurrent use of trimipramine may affect initial immunoassay results by causing false positives, but confirmatory testing prevents misinterpretation.
Key References
- SmPC: Quetiapine 300 mg film-coated tablets
- SmPC: Quetiapine 100 mg film-coated tablets
- SmPC: Quetiapine 200 mg film-coated tablets
- SmPC: Quetiapine 25 mg film-coated tablets
- NICE CKS: Opioid dependence
- NICE CG52: Drug misuse in over 16s: opioid detoxification
- NICE CG51: Drug misuse in over 16s: psychosocial interventions
- (Rapeli et al., 2009): Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals.
- (Dai et al., 2020): Quantifying enhanced risk from alcohol and other factors in polysubstance-related deaths.
- (Pani et al., 2011): Antidepressants for cocaine dependence and problematic cocaine use.